Literature DB >> 9515792

BRCA1 up-regulation is associated with repair-mediated resistance to cis-diamminedichloroplatinum(II).

A Husain1, G He, E S Venkatraman, D R Spriggs.   

Abstract

We sought to identify novel genes associated with cis-diamminedichloroplatinum(II) (CDDP) resistance, and by differential display analysis, we found that the human breast and ovarian cancer susceptibility gene BRCA1 was overexpressed in CDDP-resistant MCF-7 cells. A recent report that BRCA1 and human Rad51 colocalize in S-phase cells suggests a role for BRCA1 in DNA damage repair. We hypothesized that BRCA1 plays a role in DNA damage repair-mediated CDDP resistance. In CCDP-resistant variants of breast and ovarian carcinoma cell lines, MCF-7 CDDP/R and SKOV-3 CDDP/R, we found increased levels of BRCA1 protein, and we determined that the SKOV-3 CDDP/R cell line is significantly more proficient at DNA damage repair. Antisense inhibition of BRCA1 in this cell line resulted in an increased sensitivity to CDDP, a decreased proficiency of DNA repair, and an enhanced rate of apoptosis. These data support the hypothesis that BRCA1 is a gene involved in DNA damage repair.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9515792

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  91 in total

Review 1.  Cell cycle checkpoints as therapeutic targets.

Authors:  Z A Stewart; J A Pietenpol
Journal:  J Mammary Gland Biol Neoplasia       Date:  1999-10       Impact factor: 2.673

Review 2.  Expression of BRCA1 and BRCA2 in normal and neoplastic cells.

Authors:  L A Chodosh
Journal:  J Mammary Gland Biol Neoplasia       Date:  1998-10       Impact factor: 2.673

3.  Germline mutation in BRCA1 or BRCA2 and ten-year survival for women diagnosed with epithelial ovarian cancer.

Authors:  Francisco J Candido-dos-Reis; Honglin Song; Ellen L Goode; Julie M Cunningham; Brooke L Fridley; Melissa C Larson; Kathryn Alsop; Ed Dicks; Patricia Harrington; Susan J Ramus; Anna de Fazio; Gillian Mitchell; Sian Fereday; Kelly L Bolton; Charlie Gourley; Caroline Michie; Beth Karlan; Jenny Lester; Christine Walsh; Ilana Cass; Håkan Olsson; Martin Gore; Javier J Benitez; Maria J Garcia; Irene Andrulis; Anna Marie Mulligan; Gord Glendon; Ignacio Blanco; Conxi Lazaro; Alice S Whittemore; Valerie McGuire; Weiva Sieh; Marco Montagna; Elisa Alducci; Siegal Sadetzki; Angela Chetrit; Ava Kwong; Susanne K Kjaer; Allan Jensen; Estrid Høgdall; Susan Neuhausen; Robert Nussbaum; Mary Daly; Mark H Greene; Phuong L Mai; Jennifer T Loud; Kirsten Moysich; Amanda E Toland; Diether Lambrechts; Steve Ellis; Debra Frost; James D Brenton; Marc Tischkowitz; Douglas F Easton; Antonis Antoniou; Georgia Chenevix-Trench; Simon A Gayther; David Bowtell; Paul D P Pharoah
Journal:  Clin Cancer Res       Date:  2014-11-14       Impact factor: 12.531

Review 4.  Fine tuning chemotherapy to match BRCA1 status.

Authors:  Melissa Price; Alvaro N A Monteiro
Journal:  Biochem Pharmacol       Date:  2010-05-25       Impact factor: 5.858

5.  Outcome of triple-negative breast cancer in patients with or without deleterious BRCA mutations.

Authors:  Soley Bayraktar; Angelica M Gutierrez-Barrera; Diane Liu; Tunc Tasbas; Ugur Akar; Jennifer K Litton; E Lin; Constance T Albarracin; Funda Meric-Bernstam; Ana M Gonzalez-Angulo; Gabriel N Hortobagyi; Banu K Arun
Journal:  Breast Cancer Res Treat       Date:  2011-08-10       Impact factor: 4.872

6.  Unwrapping the implications of BRCA1 and BRCA2 mutations in ovarian cancer.

Authors:  David M Hyman; David R Spriggs
Journal:  JAMA       Date:  2012-01-25       Impact factor: 56.272

7.  Topotecan in patients with BRCA-associated and sporadic platinum-resistant ovarian, fallopian tube, and primary peritoneal cancers.

Authors:  David M Hyman; Qin Zhou; Angela G Arnold; Rachel N Grisham; Alexia Iasonos; Noah D Kauff; David Spriggs
Journal:  Gynecol Oncol       Date:  2011-08-19       Impact factor: 5.482

8.  Protein expression profiling identifies differential modulation of homologous recombination by platinum-based antitumor agents.

Authors:  Guangan He; Xiaolei Xie; Zahid H Siddik
Journal:  Cancer Chemother Pharmacol       Date:  2020-05-28       Impact factor: 3.333

9.  BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells.

Authors:  P Tassone; P Tagliaferri; A Perricelli; S Blotta; B Quaresima; M L Martelli; A Goel; V Barbieri; F Costanzo; C R Boland; S Venuta
Journal:  Br J Cancer       Date:  2003-04-22       Impact factor: 7.640

10.  Methylation and protein expression of DNA repair genes: association with chemotherapy exposure and survival in sporadic ovarian and peritoneal carcinomas.

Authors:  Elizabeth M Swisher; Rachel M Gonzalez; Toshiyasu Taniguchi; Rochelle L Garcia; Tom Walsh; Barbara A Goff; Piri Welcsh
Journal:  Mol Cancer       Date:  2009-07-14       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.